LexaGene Holdings Proposes to Amend Warrants Terms

Author's Avatar
Oct 27, 2022

BEVERLY, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated multiplex PCR testing, announces that it intends to amend the exercise price of certain common share purchase warrants (the “Warrants”) originally issued on October 29, 2019.